|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Horn SR, Stoltzfus KC, Lehrer EJ, Dawson
LA, Tchelebi L, Gusani NJ, Sharma NK, Chen H, Trifiletti DM and
Zaorsky NG: Epidemiology of liver metastases. Cancer Epidemiol.
67:1017602020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rees M, Tekkis PP, Welsh FK, O'Rourke T
and John TG: Evaluation of long-term survival after hepatic
resection for metastatic colorectal cancer: A multifactorial model
of 929 patients. Ann Surg. 247:125–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Medici B, Benatti S, Dominici M and
Gelsomino F: New frontiers of biomarkers in metastatic colorectal
cancer: Potential and critical issues. Int J Mol Sci. 26:52682025.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsubakihara Y and Moustakas A:
Epithelial-mesenchymal transition and metastasis under the control
of transforming growth factor β. Int J Mol Sci. 19:36722018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Zijl F, Krupitza G and Mikulits W:
Initial steps of metastasis: Cell invasion and endothelial
transmigration. Mutat Res. 728:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qi J and Zhu YQ: Targeting the most
upstream site of Wnt signaling pathway provides a strategic
advantage for therapy in colorectal cancer. Curr Drug Targets.
9:548–557. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rubinfeld B, Albert I, Porfiri E, Fiol C,
Munemitsu S and Polakis P: Binding of GSK3beta to the
APC-beta-catenin complex and regulation of complex assembly.
Science. 272:1023–1026. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Z, Gao Y, Qian Y, Wei B, Jiang K,
Sun Z, Zhang F, Yang M, Baldi S, Yu X, et al: The Lyn/RUVBL1
complex promotes colorectal cancer liver metastasis by regulating
arachidonic acid metabolism through chromatin remodeling. Adv Sci
(Weinh). 12:e24065622025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zubeldia IG, Bleau AM, Redrado M, Serrano
D, Agliano A, Gil-Puig C, Vidal-Vanaclocha F, Lecanda J and Calvo
A: Epithelial to mesenchymal transition and cancer stem cell
phenotypes leading to liver metastasis are abrogated by the novel
TGFβ1-targeting peptides P17 and P144. Exp Cell Res. 319:12–22.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Yang Y, Qi X, Cui P, Kang Y, Liu
H, Wei Z and Wang H: SLC14A1 and TGF-β signaling: A feedback loop
driving EMT and colorectal cancer metachronous liver metastasis. J
Exp Clin Cancer Res. 43:2082024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shin AE, Sugiura K, Kariuki SW, Cohen DA,
Flashner SP, Klein-Szanto AJ, Nishiwaki N, De D, Vasan N, Gabre JT,
et al: LIN28B-mediated PI3K/AKT pathway activation promotes
metastasis in colorectal cancer models. J Clin Invest.
135:e1860352025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun X, Zhang J, Dong B, Xiong Q, Wang X,
Gu Y, Wang Z, Liu H, Zhang J, He X, et al: Targeting SLITRK4
restrains proliferation and liver metastasis in colorectal cancer
via regulating PI3K/AKT/NFκB pathway and tumor-associated
macrophage. Adv Sci (Weinh). 12:e24003672025. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dong Z, She X, Ma J, Chen Q, Gao Y, Chen
R, Qin H, Shen B and Gao H: The E3 Ligase NEDD4L prevents
colorectal cancer liver metastasis via degradation of PRMT5 to
inhibit the AKT/mTOR signaling pathway. Adv Sci (Weinh).
2025:e25047042025. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Urosevic J, Blasco MT, Llorente A,
Bellmunt A, Berenguer-Llergo A, Guiu M, Cañellas A, Fernandez E,
Burkov I, Clapés M, et al: ERK1/2 signaling induces upregulation of
ANGPT2 and CXCR4 to mediate liver metastasis in colon cancer.
Cancer Res. 80:4668–4680. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu PC, Lin PC, Wu HY, Lin KT, Wu C,
Bekaii-Saab T, Lin YJ, Lee CT, Lee JC and Chen CS: Mutant KRAS
promotes liver metastasis of colorectal cancer, in part, by
upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling
pathway. Oncogene. 37:3440–3455. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao JF, Li XJ, Yan LK, He S, Zheng JB,
Wang XR, Zhou PH, Zhang L, Wei GB and Sun XJ: Role of HGF/c-Met in
the treatment of colorectal cancer with liver metastasis. J Biochem
Mol Toxicol. 33:e223162019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu W, Xu J, Liu J, Wang N, Zhou L and Guo
J: Liver metastasis in cancer: Molecular mechanisms and management.
MedComm (2020). 6:e701192025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dunbar KJ, Efe G, Cunningham K, Esquea E,
Navaridas R and Rustgi AK: Regulation of metastatic organotropism.
Trends Cancer. 11:216–231. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu C, Liao JY, Liu YY, Chen ZY, Chang RZ,
Chen XP, Zhang BX and Liang JN: Immune dynamics shaping
pre-metastatic and metastatic niches in liver metastases: From
molecular mechanisms to therapeutic strategies. Mol Cancer.
23:2542024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Liu F, Cai Q, Deng L, Ouyang Q,
Zhang XH and Zheng J: Invasion and metastasis in cancer: Molecular
insights and therapeutic targets. Signal Transduct Target Ther.
10:572025. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Glaire MA, Domingo E, Sveen A, Bruun J,
Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W,
et al: Tumour-infiltrating CD8+ lymphocytes and
colorectal cancer recurrence by tumour and nodal stage. Br J
Cancer. 121:474–482. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trailin A, Ali E, Ye W, Pavlov S,
Červenková L, Vyčítal O, Ambrozkiewicz F, Hošek P, Daum O, Liška V
and Hemminki K: Prognostic assessment of T-cells in primary
colorectal cancer and paired synchronous or metachronous liver
metastasis. Int J Cancer. 156:1282–1292. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang A, Zhou M, Gao Y and Zhang Y:
Mechanisms of CD8+ T cell exhaustion and its clinical
significance in prognosis of anti-tumor therapies: A review. Int
Immunopharmacol. 159:1148432025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shan T, Chen S, Wu T, Yang Y, Li S and
Chen X: PD-L1 expression in colon cancer and its relationship with
clinical prognosis. Int J Clin Exp Pathol. 12:1764–1769.
2019.PubMed/NCBI
|
|
27
|
Zhao T, Li Y, Zhang J and Zhang B: PD-L1
expression increased by IFN-γ via JAK2-STAT1 signaling and predicts
a poor survival in colorectal cancer. Oncol Lett. 20:1127–1134.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei XL, Luo X, Sheng H, Wang Y, Chen DL,
Li JN, Wang FH and Xu RH: PD-L1 expression in liver metastasis: Its
clinical significance and discordance with primary tumor in
colorectal cancer. J Transl Med. 18:4752020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rong D, Sun G, Zheng Z, Liu L, Chen X, Wu
F, Gu Y, Dai Y, Zhong W, Hao X, et al: MGP promotes CD8+
T cell exhaustion by activating the NF-κB pathway leading to liver
metastasis of colorectal cancer. Int J Biol Sci. 18:2345–2361.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun G, Zhao S, Fan Z, Wang Y, Liu H, Cao
H, Sun G, Huang T, Cai H, Pan H, et al: CHSY1 promotes
CD8+ T cell exhaustion through activation of succinate
metabolism pathway leading to colorectal cancer liver metastasis
based on CRISPR/Cas9 screening. J Exp Clin Cancer Res. 42:2482023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuwahara T, Hazama S, Suzuki N, Yoshida S,
Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu
Y, et al: Intratumoural-infiltrating CD4+ and FOXP3 + T cells as
strong positive predictive markers for the prognosis of resectable
colorectal cancer. Br J Cancer. 121:659–665. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Katz SC, Pillarisetty V, Bamboat ZM, Shia
J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M
and DeMatteo RP: T cell infiltrate predicts long-term survival
following resection of colorectal cancer liver metastases. Ann Surg
Oncol. 16:2524–2530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katz SC, Pillarisetty VG, Bleier JI,
Kingham TP, Chaudhry UI, Shah AB and DeMatteo RP: Conventional
liver CD4 T cells are functionally distinct and suppressed by
environmental factors. Hepatology. 42:293–300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu X, Wang X, Yang Q, Luo L, Liu Z, Ren
X, Lei K, Li S, Xie Z, Zheng G, et al: Th17 cells Secrete TWEAK to
trigger epithelial-mesenchymal transition and promote colorectal
cancer liver metastasis. Cancer Res. 84:1352–1371. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
De Simone V, Pallone F, Monteleone G and
Stolfi C: Role of T(H)17 cytokines in the control of colorectal
cancer. Oncoimmunology. 2:e266172013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kroemer M, Turco C, Spehner L, Viot J,
Idirène I, Bouard A, Renaude E, Deschamps M, Godet Y, Adotévi O, et
al: Investigation of the prognostic value of CD4 T cell subsets
expanded from tumor-infiltrating lymphocytes of colorectal cancer
liver metastases. J Immunother Cancer. 8:e0014782020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Olguín JE, Medina-Andrade I, Rodríguez T,
Rodríguez-Sosa M and Terrazas LI: Relevance of regulatory T cells
during colorectal cancer development. Cancers (Basel). 12:18882020.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shiri AM, Zhang T, Bedke T, Zazara DE,
Zhao L, Lücke J, Sabihi M, Fazio A, Zhang S, Tauriello DVF, et al:
IL-10 dampens antitumor immunity and promotes liver metastasis via
PD-L1 induction. J Hepatol. 80:634–644. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang X, Chen Z, Zhang N, Zhu C, Lin X, Yu
J, Chen Z, Lan P and Wan Y: Increase in
CD4+FOXP3+ regulatory T cell number and
upregulation of the HGF/c-Met signaling pathway during the liver
metastasis of colorectal cancer. Oncol Lett. 20:2113–2118. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Katz SC, Bamboat ZM, Maker AV, Shia J,
Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y,
et al: Regulatory T cell infiltration predicts outcome following
resection of colorectal cancer liver metastases. Ann Surg Oncol.
20:946–955. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brudvik KW, Henjum K, Aandahl EM,
Bjørnbeth BA and Taskén K: Regulatory T-cell-mediated inhibition of
antitumor immune responses is associated with clinical outcome in
patients with liver metastasis from colorectal cancer. Cancer
Immunol Immunother. 61:1045–1053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor-infiltrating
FOXP3+ T regulatory cells show strong prognostic significance in
colorectal cancer. J Clin Oncol. 27:186–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Saito T, Nishikawa H, Wada H, Nagano Y,
Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et
al: Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the
prognosis of colorectal cancers. Nat Med. 22:679–684. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pedroza-Gonzalez A, Verhoef C, Ijzermans
JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, Janssen HL and
Sprengers D: Activated tumor-infiltrating CD4+ regulatory T cells
restrain antitumor immunity in patients with primary or metastatic
liver cancer. Hepatology. 57:183–194. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He Y, Han Y, Fan AH, Li D, Wang B, Ji K,
Wang X, Zhao X and Lu Y: Multi-perspective comparison of the immune
microenvironment of primary colorectal cancer and liver metastases.
J Transl Med. 20:4542022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang D, Wang X, Si M, Yang J, Sun S, Wu H,
Cui S, Qu X and Yu X: Exosome-encapsulated miRNAs contribute to
CXCL12/CXCR4-induced liver metastasis of colorectal cancer by
enhancing M2 polarization of macrophages. Cancer Lett. 474:36–52.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lee YS, Song SJ, Hong HK, Oh BY, Lee WY
and Cho YB: The FBW7-MCL-1 axis is key in M1 and M2
macrophage-related colon cancer cell progression: Validating the
immunotherapeutic value of targeting PI3Kγ. Exp Mol Med.
52:815–831. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Afik R, Zigmond E, Vugman M, Klepfish M,
Shimshoni E, Pasmanik-Chor M, Shenoy A, Bassat E, Halpern Z, Geiger
T, et al: Tumor macrophages are pivotal constructors of tumor
collagenous matrix. J Exp Med. 213:2315–2331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cai J, Xia L, Li J, Ni S, Song H and Wu X:
Tumor-associated macrophages derived TGF-β-induced epithelial to
mesenchymal transition in colorectal cancer cells through
Smad2,3-4/Snail signaling pathway. Cancer Res Treat. 51:252–266.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wei C, Yang C, Wang S, Shi D, Zhang C, Lin
X, Liu Q, Dou R and Xiong B: Crosstalk between cancer cells and
tumor associated macrophages is required for mesenchymal
circulating tumor cell-mediated colorectal cancer metastasis. Mol
Cancer. 18:642019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Suarez-Lopez L, Sriram G, Kong YW,
Morandell S, Merrick KA, Hernandez Y, Haigis KM and Yaffe MB: MK2
contributes to tumor progression by promoting M2 macrophage
polarization and tumor angiogenesis. Proc Natl Acad Sci USA.
115:E4236–E4244. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhong X, Chen B and Yang Z: The role of
Tumor-associated macrophages in colorectal carcinoma progression.
Cell Physiol Biochem. 45:356–365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhao Y, Zhang W, Huo M, Wang P, Liu X,
Wang Y, Li Y, Zhou Z, Xu N and Zhu H: XBP1 regulates the protumoral
function of tumor-associated macrophages in human colorectal
cancer. Signal Transduct Target Ther. 6:3572021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang XL, Hu LP, Yang Q, Qin WT, Wang X,
Xu CJ, Tian GA, Yang XM, Yao LL, Zhu L, et al: CTHRC1 promotes
liver metastasis by reshaping infiltrated macrophages through
physical interactions with TGF-β receptors in colorectal cancer.
Oncogene. 40:3959–3973. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Huang C, Ou R, Chen X, Zhang Y, Li J,
Liang Y, Zhu X, Liu L, Li M, Lin D, et al: Tumor cell-derived SPON2
promotes M2-polarized tumor-associated macrophage infiltration and
cancer progression by activating PYK2 in CRC. J Exp Clin Cancer
Res. 40:3042021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang X, Wang J, Zhao J, Wang H, Chen J and
Wu J: HMGA2 facilitates colorectal cancer progression via
STAT3-mediated tumor-associated macrophage recruitment.
Theranostics. 12:963–975. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tu W, Gong J, Zhou Z, Tian D and Wang Z:
TCF4 enhances hepatic metastasis of colorectal cancer by regulating
tumor-associated macrophage via CCL2/CCR2 signaling. Cell Death
Dis. 12:8822021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Grossman JG, Nywening TM, Belt BA, Panni
RZ, Krasnick BA, DeNardo DG, Hawkins WG, Goedegebuure SP, Linehan
DC and Fields RC: Recruitment of CCR2+ tumor associated
macrophage to sites of liver metastasis confers a poor prognosis in
human colorectal cancer. Oncoimmunology. 7:e14707292018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y,
Chen Z, Wang L, Long Y, Hou T, et al: Fusobacterium
nucleatum promotes colorectal cancer metastasis through
miR-1322/CCL20 axis and M2 polarization. Gut Microbes.
13:19803472021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ohashi K, Wang Z, Yang YM, Billet S, Tu W,
Pimienta M, Cassel SL, Pandol SJ, Lu SC, Sutterwala FS, et al:
NOD-like receptor C4 inflammasome regulates the growth of colon
cancer liver metastasis in NAFLD. Hepatology. 70:1582–1599. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhou J, Song Q, Li H, Han Y, Pu Y, Li L,
Rong W, Liu X, Wang Z, Sun J, et al: Targeting
circ-0034880-enriched tumor extracellular vesicles to impede
SPP1highCD206+ pro-tumor macrophages mediated
pre-metastatic niche formation in colorectal cancer liver
metastasis. Mol Cancer. 23:1682024. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shao Y, Chen T, Zheng X, Yang S, Xu K,
Chen X, Xu F, Wang L, Shen Y, Wang T, et al: Colorectal
cancer-derived small extracellular vesicles establish an
inflammatory premetastatic niche in liver metastasis.
Carcinogenesis. 39:1368–1379. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Takano Y, Masuda T, Iinuma H, Yamaguchi R,
Sato K, Tobo T, Hirata H, Kuroda Y, Nambara S, Hayashi N, et al:
Circulating exosomal microRNA-203 is associated with metastasis
possibly via inducing tumor-associated macrophages in colorectal
cancer. Oncotarget. 8:78598–78613. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao S, Mi Y, Guan B, Zheng B, Wei P, Gu
Y, Zhang Z, Cai S, Xu Y, Li X, et al: Tumor-derived exosomal
miR-934 induces macrophage M2 polarization to promote liver
metastasis of colorectal cancer. J Hematol Oncol. 13:1562020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sun H, Meng Q, Shi C, Yang H, Li X, Wu S,
Familiari G, Relucenti M, Aschner M, Wang X and Chen R:
Hypoxia-inducible exosomes facilitate liver-tropic premetastatic
niche in colorectal cancer. Hepatology. 74:2633–2651. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li S, Fu X, Ning D, Liu Q, Zhao J, Cheng
Q, Chen X and Jiang L: Colon cancer exosome-associated HSP90B1
initiates pre-metastatic niche formation in the liver by polarizing
M1 macrophage into M2 phenotype. Biol Direct. 20:522025. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liang Y, Li J, Yuan Y, Ju H, Liao H, Li M,
Liu Y, Yao Y, Yang L, Li T and Lei X: Exosomal miR-106a-5p from
highly metastatic colorectal cancer cells drives liver metastasis
by inducing macrophage M2 polarization in the tumor
microenvironment. J Exp Clin Cancer Res. 43:2812024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wei X, Ye J, Pei Y, Wang C, Yang H, Tian
J, Si G, Ma Y, Wang K and Liu G: Extracellular vesicles from
colorectal cancer cells promote metastasis via the NOD1 signalling
pathway. J Extracell Vesicles. 11:e122642022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Liu Y, Zhang Q, Xing B, Luo N, Gao R, Yu
K, Hu X, Bu Z, Peng J, Ren X and Zhang Z: Immune phenotypic linkage
between colorectal cancer and liver metastasis. Cancer Cell.
40:424–437.e5. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wu Y, Yang S, Ma J, Chen Z, Song G, Rao D,
Cheng Y, Huang S, Liu Y, Jiang S, et al: Spatiotemporal immune
landscape of colorectal cancer liver metastasis at Single-cell
level. Cancer Discov. 12:134–153. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Eruslanov EB, Bhojnagarwala PS, Quatromoni
JG, Stephen TL, Ranganathan A, Deshpande C, Akimova T, Vachani A,
Litzky L, Hancock WW, et al: Tumor-associated neutrophils stimulate
T cell responses in early-stage human lung cancer. J Clin Invest.
124:5466–5480. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Fridlender ZG, Sun J, Kim S, Kapoor V,
Cheng G, Ling L, Worthen GS and Albelda SM: Polarization of
tumor-associated neutrophil phenotype by TGF-beta: ‘N1’ versus ‘N2’
TAN. Cancer Cell. 16:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Germann M, Zangger N, Sauvain MO, Sempoux
C, Bowler AD, Wirapati P, Kandalaft LE, Delorenzi M, Tejpar S,
Coukos G and Radtke F: Neutrophils suppress tumor-infiltrating T
cells in colon cancer via matrix metalloproteinase-mediated
activation of TGFβ. EMBO Mol Med. 12:e106812020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Itatani Y, Yamamoto T, Zhong C, Molinolo
AA, Ruppel J, Hegde P, Taketo MM and Ferrara N: Suppressing
neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF
antibody in a genetic model of colorectal cancer. Proc Natl Acad
Sci USA. 117:21598–21608. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gordon-Weeks AN, Lim SY, Yuzhalin AE,
Jones K, Markelc B, Kim KJ, Buzzelli JN, Fokas E, Cao Y, Smart S
and Muschel R: Neutrophils promote hepatic metastasis growth
through fibroblast growth factor 2-dependent angiogenesis in mice.
Hepatology. 65:1920–1935. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Yang L, Liu L, Zhang R, Hong J, Wang Y,
Wang J, Zuo J, Zhang J, Chen J and Hao H: IL-8 mediates a positive
loop connecting increased neutrophil extracellular traps (NETs) and
colorectal cancer liver metastasis. J Cancer. 11:4384–4396. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Tan H, Jiang Y, Shen L, Nuerhashi G, Wen
C, Gu L, Wang Y, Qi H, Cao F, Huang T, et al: Cryoablation-induced
neutrophil Ca2+ elevation and NET formation exacerbate
immune escape in colorectal cancer liver metastasis. J Exp Clin
Cancer Res. 43:3192024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Jiang Y, Long G, Huang X, Wang W, Cheng B
and Pan W: Single-cell transcriptomic analysis reveals dynamic
changes in the liver microenvironment during colorectal cancer
metastatic progression. J Transl Med. 23:3362025. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Seubert B, Grünwald B, Kobuch J, Cui H,
Schelter F, Schaten S, Siveke JT, Lim NH, Nagase H, Simonavicius N,
et al: Tissue inhibitor of metalloproteinases (TIMP)-1 creates a
premetastatic niche in the liver through SDF-1/CXCR4-dependent
neutrophil recruitment in mice. Hepatology. 61:238–248. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang H, Zhang B, Li R, Chen J, Xu G, Zhu
Y, Li J, Liang Q, Hua Q, Wang L, et al: KIAA1199 drives immune
suppression to promote colorectal cancer liver metastasis by
modulating neutrophil infiltration. Hepatology. 76:967–981. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wu J, Song J, Ge Y, Hou S, Chang Y, Chen
X, Nie Z, Guo L and Yin J: PRIM1 enhances colorectal cancer liver
metastasis via promoting neutrophil recruitment and formation of
neutrophil extracellular trap. Cell Signal. 132:1118222025.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zhang QQ, Hu XW, Liu YL, Ye ZJ, Gui YH,
Zhou DL, Qi CL, He XD, Wang H and Wang LJ: CD11b deficiency
suppresses intestinal tumor growth by reducing myeloid cell
recruitment. Sci Rep. 5:159482015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cao X, Lan Q, Xu H, Liu W, Cheng H, Hu X,
He J, Yang Q, Lai W and Chu Z: Granulocyte-like myeloid-derived
suppressor cells: The culprits of neutrophil extracellular traps
formation in the pre-metastatic niche. Int Immunopharmacol.
143:1135002024. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lim SY, Gordon-Weeks AN, Zhao L, Tapmeier
TT, Im JH, Cao Y, Beech J, Allen D, Smart S and Muschel RJ:
Recruitment of myeloid cells to the tumor microenvironment supports
liver metastasis. Oncoimmunology. 2:e231872013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Zhao L, Lim SY, Gordon-Weeks AN, Tapmeier
TT, Im JH, Cao Y, Beech J, Allen D, Smart S and Muschel RJ:
Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2
promotes the development of colorectal cancer liver metastasis.
Hepatology. 57:829–839. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chun E, Lavoie S, Michaud M, Gallini CA,
Kim J, Soucy G, Odze R, Glickman JN and Garrett WS: CCL2 promotes
colorectal carcinogenesis by enhancing polymorphonuclear
myeloid-derived suppressor cell population and function. Cell Rep.
12:244–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Inamoto S, Itatani Y, Yamamoto T,
Minamiguchi S, Hirai H, Iwamoto M, Hasegawa S, Taketo MM, Sakai Y
and Kawada K: Loss of SMAD4 promotes colorectal cancer progression
by accumulation of myeloid-derived suppressor cells through the
CCL15-CCR1 chemokine axis. Clin Cancer Res. 22:492–501. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wang D, Sun H, Wei J, Cen B and DuBois RN:
CXCL1 is critical for premetastatic niche formation and metastasis
in colorectal cancer. Cancer Res. 77:3655–3665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Dang Y, Yu J, Zhao S, Cao X and Wang Q:
HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by
regulating myeloid-derived suppressor cells. Cancer Cell Int.
22:882022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ren X, Xiao J, Zhang W, Wang F, Yan Y, Wu
X, Zeng Z, He Y, Yang W, Liao W, et al: Inhibition of CCL7 derived
from Mo-MDSCs prevents metastatic progression from latency in
colorectal cancer. Cell Death Dis. 12:4842021. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lin Q, Ren L, Jian M, Xu P, Li J, Zheng P,
Feng Q, Yang L, Ji M, Wei Y and Xu J: The mechanism of the
premetastatic niche facilitating colorectal cancer liver metastasis
generated from myeloid-derived suppressor cells induced by the
S1PR1-STAT3 signaling pathway. Cell Death Dis. 10:6932019.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang Y, Davis C, Shah S, Hughes D, Ryan
JC, Altomare D and Peña MM: IL-33 promotes growth and liver
metastasis of colorectal cancer in mice by remodeling the tumor
microenvironment and inducing angiogenesis. Mol Carcinog.
56:272–287. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Gu Y, Mi Y, Cao Y, Yu K, Zhang Z, Lian P,
Li D, Qin J and Zhao S: The lncRNA MIR181A1HG in extracellular
vesicles derived from highly metastatic colorectal cancer cells
promotes liver metastasis by remodeling the extracellular matrix
and recruiting myeloid-derived suppressor cells. Cell Biosci.
15:232025. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman
MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL and Akporiaye ET:
Transforming growth factor beta inhibits the antigen-presenting
functions and antitumor activity of dendritic cell vaccines. Cancer
Res. 63:1860–1864. 2003.PubMed/NCBI
|
|
96
|
Orsini G, Legitimo A, Failli A, Ferrari P,
Nicolini A, Spisni R, Miccoli P and Consolini R: Defective
generation and maturation of dendritic cells from monocytes in
colorectal cancer patients during the course of disease. Int J Mol
Sci. 14:22022–22041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Nagorsen D, Voigt S, Berg E, Stein H,
Thiel E and Loddenkemper C: Tumor-infiltrating macrophages and
dendritic cells in human colorectal cancer: Relation to local
regulatory T cells, systemic T-cell response against
tumor-associated antigens and survival. J Transl Med. 5:622007.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hsu YL, Chen YJ, Chang WA, Jian SF, Fan
HL, Wang JY and Kuo PL: Interaction between tumor-associated
dendritic cells and colon cancer cells contributes to tumor
progression via CXCL1. Int J Mol Sci. 19:24272018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Huang TX, Tan XY, Huang HS, Li YT, Liu BL,
Liu KS, Chen X, Chen Z, Guan XY, Zou C and Fu L: Targeting
cancer-associated fibroblast-secreted WNT2 restores dendritic
cell-mediated antitumour immunity. Gut. 71:333–344. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sun Y, Hu H, Liu Z, Xu J, Gao Y, Zhan X,
Zhou S, Zhong W, Wu D, Wang P, et al: Macrophage STING signaling
promotes NK cell to suppress colorectal cancer liver metastasis via
4-1BBL/4-1BB co-stimulation. J Immunother Cancer. 11:e0064812023.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Donadon M, Hudspeth K, Cimino M, Di
Tommaso L, Preti M, Tentorio P, Roncalli M, Mavilio D and Torzilli
G: Increased infiltration of natural killer and T cells in
colorectal liver metastases improves patient overall survival. J
Gastrointest Surg. 21:1226–1236. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dupaul-Chicoine J, Arabzadeh A, Dagenais
M, Douglas T, Champagne C, Morizot A, Rodrigue-Gervais IG, Breton
V, Colpitts SL, Beauchemin N and Saleh M: The Nlrp3 inflammasome
suppresses colorectal cancer metastatic growth in the liver by
promoting natural killer cell tumoricidal activity. Immunity.
43:751–763. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Takeda K, Hayakawa Y, Smyth MJ, Kayagaki
N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H and Okumura K:
Involvement of tumor necrosis factor-related apoptosis-inducing
ligand in surveillance of tumor metastasis by liver natural killer
cells. Nat Med. 7:94–100. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
104
|
Russo E, D'Aquino C, Di Censo C,
Laffranchi M, Tomaipitinca L, Licursi V, Garofalo S, Promeuschel J,
Peruzzi G, Sozio F, et al: Cxcr3 promotes protection from
colorectal cancer liver metastasis by driving NK cell infiltration
and plasticity. J Clin Invest. 135:e1840362025. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Harmon C, Robinson MW, Hand F, Almuaili D,
Mentor K, Houlihan DD, Hoti E, Lynch L, Geoghegan J and O'Farrelly
C: Lactate-mediated acidification of tumor microenvironment induces
apoptosis of liver-resident NK cells in colorectal liver
metastasis. Cancer Immunol Res. 7:335–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Fang H, Dai W, Gu R, Zhang Y, Li J, Luo W,
Tong S, Han L, Wang Y, Jiang C, et al: myCAF-derived exosomal PWAR6
accelerates CRC liver metastasis via altering glutamine
availability and NK cell function in the tumor microenvironment. J
Hematol Oncol. 17:1262024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Matsumura H, Kondo T, Ogawa K, Tamura T,
Fukunaga K, Murata S and Ohkohchi N: Kupffer cells decrease
metastasis of colon cancer cells to the liver in the early stage.
Int J Oncol. 45:2303–2310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wortzel I, Seo Y, Akano I, Shaashua L,
Tobias GC, Hebert J, Kim KA, Kim D, Dror S, Liu Y, et al: Unique
structural configuration of EV-DNA primes Kupffer cell-mediated
antitumor immunity to prevent metastatic progression. Nat Cancer.
5:1815–1833. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lu WP, Liu YD, Zhang ZF, Liu J, Ye JW,
Wang SY, Lin XY, Lai YR, Li J, Liu SY, et al:
m6A-modified MIR670HG suppresses tumor liver metastasis
through enhancing Kupffer cell phagocytosis. Cell Mol Life Sci.
82:1852025. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Li J, Liu XG, Ge RL, Yin YP, Liu YD, Lu
WP, Huang M, He XY, Wang J, Cai G, et al: The ligation between
ERMAP, galectin-9 and dectin-2 promotes Kupffer cell phagocytosis
and antitumor immunity. Nat Immunol. 24:1813–1824. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Bresesti C, Carito E, Notaro M, Giacca G,
Breggion S, Kerzel T, Mercado CM, Beretta S, Monti M, Merelli I, et
al: Reprogramming liver metastasis-associated macrophages toward an
anti-tumoral phenotype through enforced miR-342 expression. Cell
Rep. 44:1155922025. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Nater M, Brügger M, Cecconi V, Pereira P,
Forni G, Köksal H, Dimakou D, Herbst M, Calvanese AL, Lucchiari G,
et al: Hepatic iNKT cells facilitate colorectal cancer metastasis
by inducing a fibrotic niche in the liver. iScience. 28:1123642025.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Gassmann P, Hemping-Bovenkerk A, Mees ST
and Haier J: Metastatic tumor cell arrest in the liver-lumen
occlusion and specific adhesion are not exclusive. Int J Colorectal
Dis. 24:851–858. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Haier J, Korb T, Hotz B, Spiegel HU and
Senninger N: An intravital model to monitor steps of metastatic
tumor cell adhesion within the hepatic microcirculation. J
Gastrointest Surg. 7:507–515. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Khatib AM, Fallavollita L, Wancewicz EV,
Monia BP and Brodt P: Inhibition of hepatic endothelial E-selectin
expression by C-raf antisense oligonucleotides blocks colorectal
carcinoma liver metastasis. Cancer Res. 62:5393–5398.
2002.PubMed/NCBI
|
|
116
|
Khatib AM, Auguste P, Fallavollita L, Wang
N, Samani A, Kontogiannea M, Meterissian S and Brodt P:
Characterization of the host proinflammatory response to tumor
cells during the initial stages of liver metastasis. Am J Pathol.
167:749–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Huang WH, Zhou MW, Zhu YF, Xiang JB, Li
ZY, Wang ZH, Zhou YM, Yang Y, Chen ZY and Gu XD: The role of
hepatic stellate cells in promoting liver metastasis of colorectal
carcinoma. Onco Targets Ther. 12:7573–7580. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zeng X, Zhou J, Xiong Z, Sun H, Yang W,
Mok MTS, Wang J, Li J, Liu M, Tang W, et al: Cell cycle-related
kinase reprograms the liver immune microenvironment to promote
cancer metastasis. Cell Mol Immunol. 18:1005–1015. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yang Y, Chen Y, Liu Z, Chang Z, Sun Z and
Zhao L: Concomitant NAFLD facilitates liver metastases and
PD-1-refractory by recruiting MDSCs via CXCL5/CXCR2 in Colorectal
Cancer. Cell Mol Gastroenterol Hepatol. 18:1013512024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wang Z, Kim SY, Tu W, Kim J, Xu A, Yang
YM, Matsuda M, Reolizo L, Tsuchiya T, Billet S, et al:
Extracellular vesicles in fatty liver promote a metastatic tumor
microenvironment. Cell Metab. 35:1209–1226.e13. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Ruff SM, Brown ZJ and Pawlik TM: A review
of targeted therapy and immune checkpoint inhibitors for metastatic
colorectal cancer. Surg Oncol. 51:1019932023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Hernandez Dominguez O, Yilmaz S and Steele
SR: Stage IV colorectal cancer management and treatment. J Clin
Med. 12:20722023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Cheng XF, Zhao F, Chen D and Liu FL:
Current landscape of preoperative neoadjuvant therapies for initial
resectable colorectal cancer liver metastasis. World J
Gastroenterol. 30:663–672. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Tatsuta K, Sakata M, Kojima T, Booka E,
Kurachi K and Takeuchi H: Updated insights into the impact of
adjuvant chemotherapy on recurrence and survival after curative
resection of liver or lung metastases in colorectal cancer: A rapid
review and meta-analysis. World J Surg Oncol. 23:562025. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Yarom N and Jonker DJ: The role of the
epidermal growth factor receptor in the mechanism and treatment of
colorectal cancer. Discov Med. 11:95–105. 2011.PubMed/NCBI
|
|
126
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Au HJ, Berry SR, Krahn M, Price T, et al:
Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Final results from PRIME: Randomized phase III
study of panitumumab with FOLFOX4 for first-line treatment of
metastatic colorectal cancer. Ann Oncol. 25:1346–1355. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Choi HY and Chang JE: Targeted therapy for
cancers: From ongoing clinical trials to FDA-Approved drugs. Int J
Mol Sci. 24:136182023. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Cao D, Zheng Y, Xu H, Ge W and Xu X:
Bevacizumab improves survival in metastatic colorectal cancer
patients with primary tumor resection: A meta-analysis. Sci Rep.
9:203262019. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Tang W, Ren L, Liu T, Ye Q, Wei Y, He G,
Lin Q, Wang X, Wang M, Liang F, et al: Bevacizumab Plus mFOLFOX6
versus mFOLFOX6 Alone as First-line treatment for RAS mutant
unresectable colorectal Liver-limited metastases: The BECOME
randomized controlled trial. J Clin Oncol. 38:3175–3184. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Debeuckelaere C, Murgioni S, Lonardi S,
Girardi N, Alberti G, Fano C, Gallimberti S, Magro C,
Ahcene-Djaballah S, Daniel F, et al: Ramucirumab: The long and
winding road toward being an option for mCRC treatment. Expert Opin
Biol Ther. 19:399–409. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Tabernero J, Yoshino T, Cohn AL,
Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy
DC, Van Cutsem E, Grothey A, et al: Ramucirumab versus placebo in
combination with second-line FOLFIRI in patients with metastatic
colorectal carcinoma that progressed during or after first-line
therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine
(RAISE): A randomised, double-blind, multicentre, phase 3 study.
Lancet Oncol. 16:499–508. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Goel G: Evolution of regorafenib from
bench to bedside in colorectal cancer: Is it an attractive option
or merely a ‘me too’ drug? Cancer Manag Res. 10:425–437. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zhang Y, Zou JY, Wang Z and Wang Y:
Fruquintinib: A novel antivascular endothelial growth factor
receptor tyrosine kinase inhibitor for the treatment of metastatic
colorectal cancer. Cancer Manag Res. 11:7787–7803. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y,
Yang L, Deng Y, Chen ZD, Zhong H, et al: Effect of fruquintinib vs
placebo on overall survival in patients with previously treated
metastatic colorectal cancer: The FRESCO randomized clinical trial.
JAMA. 319:2486–2496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Dasari A, Lonardi S, Garcia-Carbonero R,
Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J,
Cubillo Gracian A, et al: Fruquintinib versus placebo in patients
with refractory metastatic colorectal cancer (FRESCO-2): An
international, multicentre, randomised, double-blind, phase 3
study. Lancet. 402:41–53. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Fusco MJ, Casak SJ, Mushti SL, Cheng J,
Christmas BJ, Thompson MD, Fu W, Wang H, Yoon M, Yang Y, et al: FDA
approval summary: Fruquintinib for the treatment of refractory
metastatic colorectal cancer. Clin Cancer Res. 30:3100–3104. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Mc Neil V and Lee SW: Advancing cancer
treatment: A review of immune checkpoint inhibitors and combination
STrategies. Cancers (Basel). 17:14082025. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch Repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in Microsatellite-Instability-High advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang
Y and Li X: Exploring immunotherapy in colorectal cancer. J Hematol
Oncol. 15:952022. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 Blockade in tumors with Mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Yu J, Green MD, Li S, Sun Y, Journey SN,
Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al: Liver
metastasis restrains immunotherapy efficacy via macrophage-mediated
T cell elimination. Nat Med. 27:152–164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Saberzadeh-Ardestani B, Jones JC,
McWilliams RR, Tougeron D, Halfdanarson TR, Guimbaud R, Hubbard JM,
Flecchia C, Shi Q, Alouani E, et al: Metastatic site and clinical
outcome of patients with deficient mismatch repair metastatic
colorectal cancer treated with an immune checkpoint inhibitor in
the first-line setting. Eur J Cancer. 196:1134332024. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Wang C, Sandhu J, Ouyang C, Ye J, Lee PP
and Fakih M: Clinical response to immunotherapy targeting
programmed cell death Receptor 1/Programmed cell death Ligand 1 in
patients with treatment-resistant microsatellite stable colorectal
cancer with and without liver metastases. JAMA Netw Open.
4:e21184162021. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Overman MJ, Lonardi S, Wong KYM, Lenz HJ,
Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill
A, et al: Durable clinical benefit with nivolumab plus ipilimumab
in DNA mismatch Repair-deficient/microsatellite instability-high
metastatic colorectal cancer. J Clin Oncol. 36:773–779. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Fukuoka S, Hara H, Takahashi N, Kojima T,
Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, et
al: Regorafenib plus nivolumab in patients with advanced gastric or
colorectal cancer: An open-label, dose-escalation, and
dose-expansion phase Ib trial (REGONIVO, EPOC1603). J Clin Oncol.
38:2053–2061. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Yang C, Zhao L, Lin Y, Wang S, Ye Y and
Shen Z: Improving the efficiency of immune checkpoint inhibitors
for metastatic pMMR/MSS colorectal cancer: Options and strategies.
Crit Rev Oncol Hematol. 200:1042042024. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Gutiu AG, Zhao L, Marrah AJ, Maher AJ,
Voss BB, Mayberry TG, Cowan BC, Wakefield MR and Fang Y: Promising
immunotherapeutic treatments for colon cancer. Med Oncol.
42:1752025. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kaviyarasan V, Das A, Deka D, Saha B,
Banerjee A, Sharma NR, Duttaroy AK and Pathak S: Advancements in
immunotherapy for colorectal cancer treatment: a comprehensive
review of strategies, challenges, and future prospective. Int J
Colorectal Dis. 40:12024. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Fatemi N, Mirbahari SN, Tierling S,
Sanjabi F, Shahrivari S, AmeliMojarad M, Amelimojarad M, Mirzaei
Rezaei M, Nobaveh P, Totonchi M and Nazemalhosseini Mojarad E:
Emerging frontiers in colorectal cancer therapy: From targeted
molecules to immunomodulatory breakthroughs and cell-based
approaches. Dig Dis Sci. 70:919–942. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Liu N, Xiao X, Zhang Z, Mao C, Wan M and
Shen J: Advances in cancer vaccine research. ACS Biomater Sci Eng.
9:5999–6023. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Liu C, Liu N, Zhang T and Tu Y: Adoptive
immune cell therapy for colorectal cancer. Front Immunol.
16:15579062025. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Pérez-Domínguez F, Quezada-Monrás C,
Cárcamo L, Muñoz JP and Carrillo-Beltrán D: Oncolytic viruses as a
novel therapeutic approach for colorectal cancer: Mechanisms,
current advances, and future directions. Cancers (Basel).
17:18542025. View Article : Google Scholar : PubMed/NCBI
|
